Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
Brunet J, Choucha Z, Gransagne M, Tabbal H, Ku M-W, Buchrieser J, Fernandes P, Batalie D, Lopez J, Ma L, Dufour E, Simon E, Hardy D, Petres S, Guinet F, Strick-Marchand H, Monot M, Charneau P, Majlessi L, Duprex WP, Gerke C, Martin A, Escriou N. Brunet J, et al. Among authors: duprex wp. J Virol. 2024 May 14;98(5):e0169323. doi: 10.1128/jvi.01693-23. Epub 2024 Apr 2. J Virol. 2024. PMID: 38563763 Free article.
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
Nambulli S, Escriou N, Rennick LJ, Demers MJ, Tilston-Lunel NL, McElroy AK, Barbeau DJ, Crossland NA, Hoehl RM, Schrauf S, White AG, Borish HJ, Tomko JA, Frye LJ, Scanga CA, Flynn JL, Martin A, Gerke C, Hartman AL, Duprex WP. Nambulli S, et al. Among authors: duprex wp. J Virol. 2024 May 14;98(5):e0176223. doi: 10.1128/jvi.01762-23. Epub 2024 Apr 2. J Virol. 2024. PMID: 38563762 Free article.
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. Klimstra WB, et al. Among authors: duprex wp. J Gen Virol. 2020 Nov;101(11):1156-1169. doi: 10.1099/jgv.0.001481. Epub 2020 Aug 21. J Gen Virol. 2020. PMID: 32821033 Free PMC article.
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients.
Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. Klimstra WB, et al. Among authors: duprex wp. bioRxiv [Preprint]. 2020 Jun 22:2020.06.19.154930. doi: 10.1101/2020.06.19.154930. bioRxiv. 2020. PMID: 32607507 Free PMC article. Updated. Preprint.
Targeting spike glycans to inhibit SARS-CoV2 viral entry.
Guseman AJ, Rennick LJ, Nambulli S, Roy CN, Martinez DR, Yang DT, Bhinderwala F, Vergara S, Schaefer A, Baric RS, Ambrose Z, Duprex WP, Gronenborn AM. Guseman AJ, et al. Among authors: duprex wp. Proc Natl Acad Sci U S A. 2023 Sep 19;120(38):e2301518120. doi: 10.1073/pnas.2301518120. Epub 2023 Sep 11. Proc Natl Acad Sci U S A. 2023. PMID: 37695910 Free PMC article.
143 results